TrialProceedings of the National Academy of Sciences of the United States of America2013

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.

Akio Iwanami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.